Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

EMA and HMA Make ACT EU Clinical Trial Scientific and CTIS Advice Pilots Permanent for 2027

EMA and HMA will make ACT EU clinical trial advice pilots permanent in January 2027, consolidating multi-country guidance for research sponsors.

Published 22 Nov 2026· 7 minute read
The Vivaldi building in Amsterdam, headquarters of the European Medicines Agency
Photo: Ceescamel / Wikimedia Commons, CC BY-SA 4.0 (cropped). Source · Licence

The European Medicines Agency and the Heads of Medicines Agencies announced that the Accelerating Clinical Trials in the EU pre-submission advice pilot will transition into a permanent initiative starting in January 2027, establishing a unified channel across the European Union for clinical trial sponsors to obtain consolidated regulatory and technical feedback before filing multi-country applications in the Clinical Trials Information System.

Consolidation of ACT EU Clinical Trial Advice

According to an official agency announcement published by the European Medicines Agency on 8 October 2026, the pre-CTA advice service will become a permanent feature of European clinical research governance in January 2027. The programme operates under the Accelerating Clinical Trials in the EU initiative, commonly known as ACT EU, which was co-founded by the European Medicines Agency, the Heads of Medicines Agencies, and the European Commission to overhaul and strengthen the clinical research ecosystem across member states.

The advice procedure is operated and coordinated by the Heads of Medicines Agencies through its Clinical Trials Coordination Group. Under this framework, trial sponsors preparing to conduct multi-state clinical investigations in Europe receive joint regulatory and technical guidance from the relevant national competent authorities before lodging a formal Clinical Trial Application in the Clinical Trials Information System. This consolidated review allows sponsors to identify and resolve dossier gaps, trial design ambiguities, and procedural discrepancies simultaneously across all intended European jurisdictions.

Prior to the establishment of the pilot in 2024, sponsors preparing multi-country trials had no mechanism for joint pre-submission engagement. Investigators and sponsors were required to request separate national scientific or regulatory advice meetings with each individual national competent authority. This fragmented process frequently generated contradictory instructions on protocol elements, trial endpoints, and monitoring strategies, causing substantial validation delays when dossiers finally entered formal assessment.

Key Procedural Details and Operating Framework

The transition from a temporary pilot to a permanent regulatory pathway formalises a streamlined pre-submission route for commercial pharmaceutical companies, small biotechnology developers, and non-commercial academic sponsors. The service is coordinated through the Clinical Trials Coordination Group working group, which convenes experts from national competent authorities to deliver coordinated feedback on key pre-submission topics in a single procedural step.

Throughout its pilot phase between 2024 and 2026, the initiative managed approximately 30 pilot applications spanning complex multi-state trials, low-intervention studies, and trials involving combination therapies. The operational scope covers critical technical and regulatory areas that sit outside traditional single-drug scientific advice, including trial classification, transition mechanics from the repealed Clinical Trials Directive, master protocols, decentralized trial elements, and compliance with harmonised ICH M11 protocol specifications.

The following table outlines the procedural and operational evolution across the three European regulatory phases:

Regulatory Dimension Pre-2024 National Framework 2024–2026 ACT EU Pilot Phase Permanent Framework from January 2027
Regulatory Authority Coordination Uncoordinated; separate submissions to each individual National Competent Authority Centralised intake via Clinical Trials Coordination Group across nominated pilot member states Permanent multi-country coordination across all Concerned Member States via CTCG
Feedback Mechanism Divergent national scientific advice letters with conflicting local requirements Single consolidated consensus report addressing technical and regulatory questions Binding consensus feedback document integrated into pre-CTIS submission workflows
Submission Platform Integration National regulatory portals with discordant documentation standards Pre-submission alignment focused on readiness for Clinical Trials Information System dossiers Standardised templates and procedures directly aligned with CTIS Part I and Part II workflows
Eligible Trial Scopes Varies by individual country; limited access for multinational academic consortia Approximately 30 selected pilot applications testing procedural feasibility Routine access for all commercial and non-commercial multinational trial sponsors
Guidance and Documentation Disparate national guidelines and non-standardised submission briefing packages Interim pilot guidance and experimental application templates Permanent guidance documents and standardised sponsor templates on CTCG portal

Regulatory Context Under Regulation EU No 536/2014

The permanent advice service represents a cornerstone of the broader modernization underway across the European clinical trials landscape. The European Union fully transitioned to Regulation (EU) No 536/2014, the Clinical Trials Regulation, which replaced the fragmented 2001 Clinical Trials Directive and mandated the exclusive use of the Clinical Trials Information System for all new clinical trial applications and legacy trial transitions. As documented in industry reporting by Clinical Trials Arena, creating a unified regulatory portal was a crucial step, but operational friction persisted when sponsors encountered divergent national interpretations during formal Part I scientific evaluation and Part II national ethical review.

ACT EU was established to dismantle these remaining barriers through ten targeted priority actions. Priority Action 7 explicitly tasked the Clinical Trials Coordination Group with establishing consolidated advice pathways, bridging the gap between the Scientific Advice Working Party at the European Medicines Agency, which primarily addresses drug development endpoints and marketing authorization strategy, and national competent authorities responsible for trial authorization and site safety. The permanent advice framework ensures that early trial design aligns seamlessly with rigorous standards for clinical trial protocol design before applications are formally registered.

Stakeholder Reception and Strategic Policy Alignment

The decision to make pre-submission advice permanent has been welcomed by regulatory professionals and industry associations seeking greater predictability in European drug development. An analysis published by the Regulatory Affairs Professionals Society emphasized that establishing a permanent advice procedure directly reinforces the European Commission strategic objectives for the European Biotech Act. The European Biotech Act is designed to streamline administrative pathways, accelerate clinical development timelines, and reverse the gradual decline of early-phase trial starts across the continent relative to the United States and the Asia-Pacific region.

Regulatory experts have highlighted that the permanent mechanism provides Europe with a collaborative equivalent to the Pre-IND meeting framework administered by the United States Food and Drug Administration. While the FDA system relies on a single national agency, the ACT EU framework achieves multi-jurisdictional alignment among sovereign member states before dossier validation. This pre-submission consensus substantially reduces the risk of protracted Requests for Information during assessment, which have historically caused unexpected trial delays and budgetary overruns for biopharmaceutical developers.

Implications for University Sponsors and Research Offices

For university sponsors, academic medical centers, and clinical trial offices, the permanent ACT EU advice framework addresses a long-standing operational vulnerability. Non-commercial sponsors frequently design multinational academic trials to evaluate rare diseases, pediatric indications, or repurposed therapies, but often lack dedicated regulatory affairs departments in multiple European capitals. A detailed clinical research report by MedPath Trial noted that managing divergent competent authority expectations across six to twelve member states historically created severe operational burdens that disproportionately discouraged academic research consortia.

Academic research administrators must adapt their pre-award and protocol finalization timelines to leverage the permanent pathway effectively. When developing a multi-country clinical trial protocol, trial management teams should schedule pre-CTA advice requests at least four to six months prior to their planned submission target in CTIS. Research offices must ensure that trial documentation accounts for both technical trial design and downstream compliance obligations, including prospective trial registration and mandatory results disclosure governed by clinical trial registration and reporting compliance mandates.

University grant offices should also factor the procedural timelines into grant milestones and sponsor-investigator budgets. Early engagement through the Clinical Trials Coordination Group minimizes subsequent dossier revisions, prevents costly protocol amendments after authorization, and facilitates uniform patient safety standards across all academic medical centers participating in the consortium.

Implementation Roadmap and Next Milestones

The transition to the permanent framework follows a structured regulatory roadmap outlined by European authorities. The pilot initiative will remain active through the end of 2026, continuing to process applications currently under review and accepting qualifying requests within its initial scope. Officials confirmed that insights gathered across the approximately 30 pilot procedures will be compiled into a comprehensive evaluation report scheduled for public release before the end of 2026.

Following the publication of the evaluation report, updated guidance documents, briefing templates, and revised submission instructions will be officially released on the Clinical Trials Coordination Group website in January 2027. Sponsoring organizations planning multi-site European investigations for 2027 and 2028 are advised to review the forthcoming templates to ensure their pre-submission dossiers align with the finalized procedural standards.

Sources

Ask CASRAI · full access

Ask about this story

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →